Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in …7thSpace Interactive (press release)The incidence of renal cell cancer (RCC) has been increasing for the past decade, and the 5-year survival for patients with metastatic RCC (m…
Utilizing Everolimus and Sunitinib in pNETsOncLiveIn May 2011, the FDA approved sunitinib (Sutent) for the treatment of progressive well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable, locally advanced, or metastat…
High Dose Corticosteroids May Reduce Corrosive-Induced Esophageal StricturesMonthly Prescribing ReferenceHigh doses of a corticosteroid may help reduce esophageal strictures in children who have ingested caustic substances, according to a new study in …
CENTURY II: Bioresorbable Polymer DES Stands up to Everolimus-Eluting DeviceTCTMDA randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terum…
|
APPOSITION IV: Self-Expanding SES Covers Struts Better, Faster than Balloon …
TCTMD PARIS, France—A self-apposing sirolimus-eluting stent (SES) shows ‘excellent’ apposition over time—better than an existing balloon-expandable drug-eluting stent—in patients with ST-segment elevation myocardial infarction (STEMI), according to a … |
MedscapeTopical Tacrolimus 0.03% as Sole Therapy in Vernal KeratoconjunctivitisMedscapeRecent clinical trials have also shown that, like corticosteroids, tacrolimus and other immunosuppressive drugs have similar efficacy in allergic crisis control and …
Next Steps for Everolimus in Metastatic Breast CancerOncLiveTo explore this further, the phase II BOLERO-4 trial is examining everolimus plus letrozole as first-line therapy in ER-positive, HER2-negative metastatic breast cancer, adds Hope S. Rugo, MD….
Using cyclosporine A: Study sheds light on inflammatory mechanisms in atopic …Skin and Allergy News Digital NetworkDisclosures: Ms. Rozenblit reported no conflicts of interest. The National Institutes of Health, Rockefeller University, and a Dermatol…
RADIANT-3 Trial: Everolimus for Patients With pNETsOncLiveThe utilization of the mTOR inhibitor everolimus as a treatment for patients with pancreatic neuroendocrine tumors (pNET) has increased since the FDA first approved the drug in this space in 201…
|
Topical Corticosteroids: 10 Must-Know Facts
Pharmacy Times For patients with all kinds of skin problems, topical corticosteroids—prescription and OTC strength—are often soothing, as well as generally safe and effective.1 Let’s review 10 facts about these topicals. 1. Skin disorders prompt many physician … |